System Labs lists sermorelin in two forms: an injection from $219/month with a discounted first month from $109, and an oral compounded form from $159/month with a discounted first month from $79 (System Labs' published treatment inventory, checked 29 August 2026). The first-month rate reverts to the ongoing price after month one and each treatment is billed separately, which makes the injectable route the most expensive single item on the published menu.
Sermorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH). It prompts the pituitary gland to release more of the body's own growth hormone rather than supplying growth hormone itself — a distinction worth holding on to, because it is not HGH therapy and should not be read as equivalent to it. Its regulatory history is unusual and is often quoted in a misleading way: it was FDA-approved as Geref in 1997, but EMD Serono told the FDA the product was no longer marketed and asked for the approval to be withdrawn, which took effect in June 2009. The FDA later determined that Geref was not withdrawn from sale for reasons of safety or effectiveness; it records no positive reason, so the “withdrawn for commercial reasons” shorthand often repeated around sermorelin claims more than the FDA actually says. That history says nothing about its status today. Sermorelin is now supplied as a compounded medication, compounded products are not reviewed by the FDA as finished goods, and there is no current approval for anti-ageing, body-composition or general wellness use.
On evidence, marketing around growth-hormone secretagogues tends to run well ahead of long-term human outcome data, and evidence in healthy adults is limited — so strong claims about muscle, fat loss or slowing ageing deserve caution rather than confidence. Sermorelin also sits on the WADA prohibited list, so any athlete subject to testing should treat it as banned. As with every System Labs treatment, access requires a licensed clinician evaluation first. This section describes what System Labs lists and what the treatment is; it does not recommend sermorelin and gives no dosing, protocol or suitability guidance, which are matters for the prescribing clinician.